Novo Nordisk A/S

Informe acción NYSE:NVO

Capitalización de mercado: US$441.7b

Novo Nordisk Dirección

Dirección controles de criterios 3/4

El CEO de Novo Nordisk es Lars Jorgensen, nombrado en Jan 2017, tiene una permanencia de 7.83 años. posee directamente un 0.002% de las acciones de la empresa, con un valor de $9.23M. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 6.7 años, respectivamente.

Información clave

Lars Jorgensen

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO7.8yrs
Participación del CEO0.002%
Permanencia media de la dirección3.8yrs
Promedio de permanencia en la Junta Directiva6.7yrs

Actualizaciones recientes de la dirección

No hay actualizaciones

Recent updates

Novo Nordisk: A GLP-1 Leader Faces Increasing Competition

Nov 06

Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued

Oct 21

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

Sep 18

Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now

Sep 10

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Aug 07

Novo Nordisk: Better Buying Opportunities Ahead

Jul 26

Novo Nordisk: Buy On Dips

Jul 04

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Jun 26

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Jun 18

Novo Nordisk: Considerable Growth Beyond Ozempic

May 27

The FTC Cracks Down On Novo Nordisk's Ozempic

May 03

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Apr 26

Novo Nordisk: The Moat Won't Last Forever

Apr 09

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Mar 18

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Mar 07

Novo Nordisk, A Very Healthy Pharma Stalwart

Feb 28

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Lars Jorgensen en comparación con los beneficios de Novo Nordisk?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

DKK 95b

Jun 30 2024n/an/a

DKK 90b

Mar 31 2024n/an/a

DKK 89b

Dec 31 2023n/an/a

DKK 84b

Sep 30 2023n/an/a

DKK 75b

Jun 30 2023n/an/a

DKK 67b

Mar 31 2023n/an/a

DKK 61b

Dec 31 2022DKK 60mDKK 17m

DKK 56b

Sep 30 2022n/an/a

DKK 53b

Jun 30 2022n/an/a

DKK 51b

Mar 31 2022n/an/a

DKK 49b

Dec 31 2021DKK 58mDKK 17m

DKK 48b

Sep 30 2021n/an/a

DKK 46b

Jun 30 2021n/an/a

DKK 44b

Mar 31 2021n/an/a

DKK 43b

Dec 31 2020DKK 57mDKK 14m

DKK 42b

Sep 30 2020n/an/a

DKK 42b

Jun 30 2020n/an/a

DKK 41b

Mar 31 2020n/an/a

DKK 40b

Dec 31 2019DKK 55mDKK 14m

DKK 39b

Sep 30 2019n/an/a

DKK 39b

Jun 30 2019n/an/a

DKK 38b

Mar 31 2019n/an/a

DKK 38b

Dec 31 2018DKK 41mDKK 11m

DKK 39b

Sep 30 2018n/an/a

DKK 38b

Jun 30 2018n/an/a

DKK 39b

Mar 31 2018n/an/a

DKK 39b

Dec 31 2017DKK 32mDKK 9m

DKK 38b

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Lars es razonable en comparación con empresas de tamaño similar en el mercado US.

Compensación vs. Ingresos: La compensación de Lars ha sido consistente con los resultados de la empresa en el último año.

CEO

Lars Jorgensen (58 yo)

7.8yrs

Permanencia

DKK 60,100,000

Compensación

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Lars Jorgensen
President7.8yrsDKK 60.10m0.0021%
$ 9.2m
Karsten Knudsen
Executive VP6.8yrsDKK 21.50m0.000010%
$ 44.2k
Henrik Wulff
Executive VP of Product Supplyno dataDKK 22.00m0.000060%
$ 265.0k
Camilla Sylvest
Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Boardno dataDKK 21.30msin datos
Martin Lange
Executive VP of Development & Member of the Management Board3.8yrsDKK 20.90msin datos
Marcus Schindler
EVP of Research & Early Development3.7yrsDKK 20.90msin datos
Maziar Doustdar
Executive VP of International Operations & Member of the Management Boardno datasin datos0.0011%
$ 5.0m
Douglas Langa
Executive VP of North America Operations & Member of Management Boardno datasin datossin datos
Ludovic Helfgott
Executive VPno datasin datossin datos
Tania Sabroe
Executive VP of Global People & Organisation and Member of Management Board1.7yrssin datossin datos
David Moore
Executive VP of Corporate Development & Member of Management Board1.7yrssin datossin datos
Jacob Martin Rode
Head of Investor Relationsno datasin datossin datos

3.8yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NVO se considera experimentado (3.8 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Sylvie Gregoire
Independent Director9.7yrsDKK 1.80msin datos
Helge Lund
Independent Chairman of the Board7.7yrsDKK 3.10msin datos
Henrik Poulsen
Vice Chairman of the Board3.7yrsDKK 2.00msin datos
Laurence Debroux
Independent Director5.7yrsDKK 2.00msin datos
Martin MacKay
Independent Director6.7yrsDKK 1.70msin datos
Andreas Fibig
Independent Director6.7yrsDKK 1.40msin datos
Kasim Kutay
Non-Independent Director7.7yrsDKK 1.20msin datos
Christina Law
Independent Director2.7yrsDKK 1.30msin datos
Liselotte Hyveled
Employee Representative Director2.7yrsDKK 800.00k0%
$ 0
Mette Jensen
Employee Non-Independent Representative Director6.7yrsDKK 1.20msin datos
Thomas Rantzau
Employee Representative Non-Independent Director6.8yrsDKK 1.00msin datos
Elisabeth Christensen
Employee Representative Director2.7yrsDKK 800.00ksin datos

6.7yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de NVO se considera experimentada (6.7 años de antigüedad promedio).